Cedilla Therapeutics Inc. has synthesized cyclin-dependent kinase 2 (CDK2)/cyclin E1 inhibitors reported to be useful for the treatment of cancer, autoimmune diseases, Cushing syndrome, Alzheimer's disease, hepatic fibrosis, viral infections, inflammatory disorders and polycystic kidney.